Form 4: BioAge Labs Principal Accounting Officer Acquires 40,000 Stock Options

BioAge Labs' Principal Accounting Officer, Shane Barton, was granted 40,000 stock options on December 18, 2024, according to a recent SEC filing.

Summary

• Shane Barton, the Principal Accounting Officer of BioAge Labs, Inc., was granted 40,000 stock options on December 18, 2024.
• The options have an exercise price of $4.30 per share.
• The options vest monthly over a four-year period, with the first vesting date on October 26, 2024.
• The options expire on December 17, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating a positive alignment of interests between management and the company. It is not a major event but is a positive sign.

Positives

• The grant of stock options aligns the interests of the Principal Accounting Officer with the company's long-term performance.
• The vesting schedule encourages continued service to the company.

Industry Context

Stock option grants are a common form of compensation for executives and key employees in the biotechnology industry, aligning their interests with the company's success.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize key personnel.
• The vesting schedule of 48 months is typical for such grants, ensuring long-term commitment.
• The exercise price of $4.30 is specific to BioAge Labs and its current valuation.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment as it aligns management's interests with the company's performance.

Key Dates

Keywords

stock options, insider trading, SEC Form 4, equity compensation, BioAge Labs, Shane Barton, vesting